Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+(IHC3+) gastric carcinoma (GC).

被引：13

作者：

Catenacci, Daniel V. T.

Lim, Kian Huat

Uronis, Hope Elizabeth

Kang, Yoon-Koo

Ng, Matthew C. H.

Gold, Philip Jordan

Enzinger, Peter C.

Lee, Keun Wook

Lacy, Jill

Park, Se Hoon

Yen, Jennifer

Odegaard, Justin

Franovic, Aleksandra

Baughman, Jan E.

Wynter-Horton, Aisha

Chen, Francine

Moore, Paul A.

Wu, Tony

Davidson-Moncada, Jan Kenneth

Bang, Yung-Jue

机构：

[1] Univ Chicago, Med Ctr & Biol Sci, Chicago, IL 60637 USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Asan Med Ctr, Dept Oncol, Seoul, South Korea

[5] Natl Canc Ctr Singapore, Singapore, Singapore

[6] Swedish Canc Inst, Seattle, WA USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[9] Yale Univ, Smilow Canc Hosp, New Haven, CT USA

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[11] Guardant Hlth Inc, Redwood City, CA USA

[12] Lifecode, San Francisco, CA USA

[13] MacroGenics Inc, Rockville, MD USA

[14] Seoul Natl Univ Hosp, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.65

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2